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 Isoindolinones via Copper-Catalyzed Intramolecular Benzylic 
C-H Sulfamidation. 
Robin B. Bedford,* John G. Bowen and Carolina Méndez-Gálvez  
School of Chemistry, University of Bristol, Bristol BS8 1TS, U.K.  
KEYWORDS Copper, C-H activation, amidation, sulfamidation.  
ABSTRACT: 2-Benzyl-N-tosylbenzamides and related substrates undergo copper-catalyzed intramolecular sulfamidation 
at the benzylic methylene to give N-arylsuflonyl-1-arylisoindolinones, which can be N-deprotected using samarium iodide 
to generate the free 1-arylisoindolinones. Preliminary mechanistic studies indicate that the rate-determining step is not C-
H bond cleavage, but are instead consistent with slow oxidation of a copper -arene intermediate.
Introduction 
The isoindolinone core is a privileged structure with exam-
ples showing a range of biological functions and medicinal 
applications.1 For instance pazinaclone (Figure 1) has 
demonstrated anxiolytic properties,2 1 is a dopamine recep-
tor antagonist,3 2 shows antiretroviral activity,4 lenalido-
mide is used in the treatment of multiple myeloma,5 whilst 
pestalachloride A, isolated from the fungus Pestalotiopsis 
adusta, is reported to have significant anti-microbial activ-
ity.6 
 
 
Figure 1. Examples of biologically active isoindolinones. 
 
Catalytic intramolecular sp3-C-H amidation represent an 
excellent approach to the synthesis of N-heterocycles,7 and 
inspired by recent reports of catalytic benzylic C-H amina-
tion,8,9 we wondered whether such an approach could be 
applied to the synthesis of N-sufonyl isoindolinones via C-
H sulfamidation. Such sulfamidation routes would be pref-
erable to recently reported catalyzed or catalyst-free ami-
dation reactions with N-aryl substrates,10,11 as the products 
should undergo comparatively facile N-deprotection to 
yield the free isoindolinones. 
 
Results and Discussion 
In the first instance, we undertook an optimisation study, 
examining the copper-catalysed12 cyclisation of substrate 
3a, which could be easily prepared in one step from ben-
zylbenzoic acid and p-toluenesulfonyl isocyanate, to the 
isoindolinone 4a, and the results from this study are sum-
marised in Table 1. 
 
Table 1. Optimisation of the reaction conditions. 
 
Entry Cu(OTf)2 
loading 
(mol%) 
Oxidant 
(equiv.) 
Solvent 
(v:v) 
Temp. 
(°C) 
Yield 
4aa 
(%) 
1 0 PhI(OAc)2 
(4) 
DCE 120 0 
2 50 “ “ “ 41 
3b “ “ “ “ 12 
4c “ “ “ “ 21 
5 “ HTIB (4) “ “ 0 
6 “ PIFA (4) “ “ 0 
 7 “ PhI(OAc)2 
(4) 
AcOH “ 9 
8 “ “ DCE/ 
AcOH 
(5:1) 
“ 51 
9 “ “ CHCl3/
AcOH 
(5:1) 
“ 43 
10 “ “ PhCl/ 
AcOH 
(5:1) 
“ 60 
11 “ PhI(OAc)2 
(2) 
“ “ 58 
12  20 “ “ “ 71 
13 10 “ “ “ 20 
14 20 “ PhCl/ 
TFA 
(5:1) 
“ 0 
15 “ “ PhCl/ 
AcOH 
(5:1) 
140 48 
16 “ “ “ 100 15 
a. Spectroscopic yield determined by 1H NMR (1,3,5-
C6H3(OMe)3 internal standard). b. Under N2. c. Under O2 
 
In the absence of catalyst, no conversion to the desired 
product was observed under air, using four equivalents of 
phenylidonium diacetate as the oxidant and 1,2-dichloro-
ethane (DCE) as the solvent (entry 1). Adding a high load-
ing of copper (II) triflate (50 mol%, entry 2) led to a rea-
sonable amount of the desired product, however the reac-
tion was clearly not catalytic. Repeating the reaction under 
inert conditions or under O2 proved deleterious (entries 3 
and 4). Replacing PhI(OAc)2 with either  hydroxy(to-
syloxy)iodobenzene (HTIB) or PhI(O2CCF3)2 (PIFA) shut 
down the reaction (entries 5 and 6). While the use of neat 
acetic acid as solvent was deleterious (entry 7), the use of 
acetic acid in chlorinated solvents proved beneficial (en-
tries 8 – 10), with the best activity obtained using chloro-
benzene. With this solvent system, both the amount of ox-
idant (2 equiv.) and the catalyst loading (20 mol%) could 
be reduced, to give the optimum conditions indicated in 
entry 12. Reducing the catalyst loading further proved to be 
detrimental, as did either replacing acetic acid with tri-
fluoroacetic acid (entry 14) or changing the temperature 
(entries 15 and 16). 
With optimised conditions in hand, we next 
briefly explored the range of substrates that undergo the 
intramolecular sulfamidation reaction. The successful re-
sults are summarised in Table 2, whilst the substrates that 
failed to cyclise are shown in Figure 2. 
Diarylmethane-based substrates with electron-
withdrawing and -donating groups on either of the aryl 
rings underwent the desired reaction to generate the iso-
indolinones 4a – 4i. Interestingly, C-H functionalization at 
a tertiary carbon center was also achieved, yielding the 
product 4j in moderate yield. In contrast with Kondo’s re-
lated amidation reactions with N-aryl precursors,10 the sul-
famidation reaction fails for the substrate 3m. While it is 
tempting to conclude from this that two aryl groups are re-
quired at the benzylic center for electronic reasons, this is 
clearly not the case in the formation of the 4k. Instead it 
appears that a ‘pro-exocyclic’ arene substituent is required 
for activity. In addition to the requirement for a pro-exo-
cyclic arene, it appears that the benzylic site of C-H func-
tionalization must be incorporated into a structurally rigid 
framework. Thus while 4k is formed, no cyclisation is ob-
served with the conformationally flexible substrate 4n, 
suggesting that the transition state for C-H activation re-
quires a sulfonamide-coordinated copper complex to be 
held in close proximity to the reactive center. 
 
Table 2. Successful C-H sulfamidation reactions.a 
 
 
   
   
   
  
 
a. Isolated yields. b. Spectroscopic yield determined by 
1H NMR (1,3,5-C6H3(OMe)3 internal standard). 
 
   
Figure 2. Substrates that failed to cyclize. 
 
The formation of 4l demonstrates that the reac-
tion can be extended to sulfamidation with the p-nosyl 
function. Importantly, both 4l and the related tosyl-con-
taining 4b undergo ‘instantaneous’ samarium-mediated 
deprotection13 to yield the free NH-isoindolinone, 5 
(Scheme 1). 
 
Scheme 1. Deprotection of N-sulfonyl isoindolinones. 
 
 
In order to gain further mechanistic insight, we 
followed the formation of the products 4a – f against time 
from their precursors 3a – f, and the results of this study 
are summarized in Figure 3. It is immediately apparent that 
the reaction is favored by electron-donating groups on the 
pro-exocyclic arene, with the p-anisyl-based substrate 3c 
giving by far the highest rate, with maximum conversion 
obtained prior to the first sampling point. Furthermore, 
the reactions with all the other substrates examined show 
pronounced induction periods of around 5 – 10 minutes be-
fore onset of catalytic activity. Whatever the catalyst acti-
vation process is, it is clear that it is substrate-dependent. 
 
 
Figure 3. Formation of 4a – f over time. Spectroscopic yields 
determined by 1H NMR (1,3,5-C6H3(OMe)3 internal standard).  
 
 
The role of the electronics of the pro-exocyclic 
ring on the rate-determining step of the reaction was 
probed by a Hammett analysis of the reactions (Figure 4), 
based on the observed maximum rates. The plot against  
gave a poor correlation whilst that against + gave a mod-
erate R2 of 0.79, and  ≈ -1.4.14 This suggests that rate-de-
termining step involves loss of electron density.15 
 
 
 
Figure 4. Hammett correlation of maximum rate against both 
( ) and + ()values. 
 
In order to determine whether or not C-H bond-
cleavage features in the rate-limiting step in the catalytic 
cycle, we undertook a variety of kinetic isotope effect stud-
ies. Subjecting 3a and its di-deuterated analog 3a-D2 to cy-
clisation under identical conditions gave the same rate of 
formation of the products 3a and 3a-D (kH = 0.062 
mM/min; kD = 0.063 mM/min).16 Similarly, a competition 
reaction, containing equal amounts of 3a and 3a-D2, 
quenched at approximately 30% conversion, gave a prod-
uct mixture containing equal amounts of 4a and 4a-D. The 
lack of a kinetic isotope effect in both cases indicates that 
C-H bond-cleavage is not involved in the rate-determining 
step.17 By contrast, subjecting the 2:1 mixture of the deuter-
ium-enriched substrate 3a-HD and 3a to the standard re-
action gave a 3:2 ratio of 4a and 4a-D, which corresponds 
to a KIE of 1.5. These KIE data are consistent with the rate-
determining step involving substrate interaction with the 
copper and occurring prior to the C-H functionalization 
step.17 Consistent with this suggestion is the observation 
that the relative rate data above shows a strong influence 
of the electronics of the exocyclic arene on the rate of ca-
talysis.  
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Any mechanistic proposal must address the following 
observations: 
(i) A pro-exocyclic aryl group is essential for activ-
ity; 
(ii) The sulfonamide and benzyl functions must be 
held proximate within a stereochemically rigid 
framework;  
(iii) The rate-determining step is accelerated by in-
creasing electron-density on the pro-exocyclic 
aryl ring, but does not involve C-H cleavage and 
likely occurs before C-H activation; 
(iv) The high sensitivity of the reaction to the pre-
cise nature of the oxidant. 
One possible explanation that can satisfy all of these crite-
ria is the involvement of an n-arene-coordinated copper 
intermediate of the type I (Figure 5), which undergoes slow 
oxidation, facilitated by increasing electron-density on the 
aryl ring. It has been suggested that a copper (I)/(III) man-
ifold is active in many C-H functionalization processes,18 in 
which case I would contain Cu(I). While we do not have 
direct evidence for such a species at present, stable Cu(I) 
arene -complexes with 1-, 2- and even 6-arene interac-
tions are known.19 Meanwhile a DFT examination of a 
model of I, I* (L = H2O; phenylene backbone)16 returned a 
plausible ground-state structure with an 2-arene interac-
tion (Figure 5). 
The calculated Cu-C distances of 2.15 and 2.25 Å 
are comparable with the bond metrics associated with pre-
viously reported, structurally characterized Cu(I) arene 
complexes, 6.19e The DFT analysis suggests that the bond-
ing interaction between the 2-arene function and the cop-
per center has both  and -symmetry components. Inter-
estingly, Fukuzumi and Itoh showed that both the redox 
potential and the rate of oxidation of the complexes 6 is 
strongly dependent on the electronic properties of the sub-
stituted arene, with more facile oxidation occurring with 
inductive substituents.19e In the reaction of 6 with oxygen, 
the oxidation rate increases with decreasing Cu-arene sta-
bility, which is in turn associated with a less electron-rich 
arene, suggesting that formation of the bridging peroxo 
LCu-O2-CuL occurs after arene dissociation.19e In contrast, 
our data indicate an increased rate of reaction with more 
electron-rich arenes suggesting that the oxidation of the 
copper occurs prior to arene decoordination, consistent 
with Fukuzumi and Itoh’s electrochemical oxidations.19e 
With regards to the subsequent C-H activation step, this 
may well occur by a radical pathway as evidenced by the 
suppression of cyclization of 3a in the presence of two 
equivalents of TEMPO and the recovery of >95% of the 
starting material. 
 
 
 
I* 
 
Figure 5. Top: Putative generalized Cu-arene intermediates, I 
and previously reported Cu(I) 2-arene complex, 6.19e  Middle: 
DFT computational model, I* (B3LYP-D3BJ/6-311+G(p,d). Bot-
tom: HOMO-10 (left) and HOMO-9 (right), hydrogens omit-
ted for clarity, isovalue = 0.05 (electron/bohr3)1/2.  
 
Conclusion 
In summary we have developed the copper-catalyzed syn-
thesis of isoindolinones via a tolylsulfonamide- or nosyl-
sulfonamide-directed C-H functionalization, a process in 
which the sulfonamide acts as both the directing group and 
the functionalizing reagent. Subsequent samarium-medi-
ated removal of the sulfonyl function leads to the free iso-
indolinone. The substrate scope of the reaction and the re-
sults from preliminary mechanistic and computational 
studies point to the possible involvement of arene -coor-
dination in the rate-determining step of the reaction, 
which may well be oxidation of the copper center. We are 
currently probing this putative mechanism more deeply 
with a view to exploiting it in novel catalytic processes, and 
the results of these studies will be presented in due course.  
 
Experimental Section 
General Experimental Information. Reagents were used 
as supplied from commercial sources. Anhydrous THF was 
obtained from a purification column composed of acti-
vated alumina and subsequently stored under nitrogen. All 
other anhydrous solvents were prepared by drying the cor-
responding reagent grade solvent over molecular sieves. 
 Mass Spectrometry was carried out with a MicrOTOF II 
spectrometer (Electrospray (ESI), with a time-of-flight 
(TOF) analyzer type. 
General Procedure for the Preparation of Substrates, 
3. Following a reported procedure,20 p-toluenesulfonyl iso-
cyanate (592 mg, 3 mmol) was added to a solution of the 
appropriate 2-benzylbenzoic acid (1 eq) in THF (0.5 M so-
lution) and stirred at room temperature for 10 minutes. Tri-
ethylamine (306 mg, 3 mmol) was added dropwise to the 
solution with evolution of gas and the reaction progress 
was monitored using an oil bubbler. Upon completion of 
the reaction (typically 3 h) ethyl acetate and aqueous HCl 
(2M) were added to the mixture. The organic phase was 
washed with brine and dried over MgSO4. The volatiles 
were removed under reduced pressure and the resulting 
solid was purified by recrystallisation from ethyl acetate: 
petroleum ether (60/80) (1:4) to give the pure product. 
2-Benzyl-N-tosylbenzamide (3a). White solid (0.90 g, 
82%).The spectroscopic data are in agreement with litera-
ture 21, m.p. 156-157 °C; 1H NMR (400 MHz, CDCl3) δ 2.44 
(s, 3H), 4.05 (s, 2H), 6.90 – 6.99 (m, 2H), 7.08 – 7.27 (m, 
5H), 7.27 – 7.46 (m, 4H), 7.93 (d, J = 8.0 Hz, 2H), 8.44 (s, 
1H, NH); 13C NMR (101 MHz, CDCl3) δ 21.8, 38.4, 126.2, 126.6, 
127.7, 128.5, 128.6, 128.8, 129.6, 131.6, 131.9, 132.5, 135.5, 140.1, 
140.6, 145.1, 166.3; IR: 3066, 2862, 1672, 1575, 1594, 1493, 1440, 
1351, 1255; IR (neat, cm-1): 3065, 2861, 1672, 1594, 1574, 1493, 
1439, 1351, 1255, 1167; 1075.72; HRMS (ESI): calcd for 
C21H20NO3S [(M+H)+]: 366.1158,  found 366.1164. 
 2-(4-Methylbenzyl)-N-tosylbenzamide (3b). White 
solid (0.95 g, 83%), m.p. 116 – 117 °C; 1H NMR (400 MHz, 
CDCl3) δ 2.28 (s, 3H), 2.46 (s, 3H), 4.02 (s, 2H), 6.85 (d, J = 
7.8 Hz, 2H), 6.96 (d, J = 7.7 Hz, 2H), 7.18 – 7.25 (m, 2H), 
7.30 – 7.46 (m, 4H), 7.96 (d, J = 8.2 Hz, 2H), 8.51 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 21.0, 21.7, 37.9, 126.4, 127.7, 128.5, 
128.6, 129.2, 129.5, 131.4, 131.8, 132.4, 135.4, 135.6, 136.9, 140.7, 
145.0, 166.3; IR (neat, cm-1): 3350, 3258, 1669, 1597, 1488, 
1305, 1153, 1093, 900; HRMS (ESI): calcd for C22H22NO3S 
[(M+H)+]: 380.1315, found 380.1316. 
2-(4-Methoxybenzyl)-N-tosylbenzamide (3c). White solid 
(1.07 g, 91%), m.p. 136 – 137 °C; 1H NMR (400 MHz, CDCl3) 
δ 2.47 (s, 3H), 3.76 (s, 3H), 4.01 (s, 2H), 6.66 – 6.72 (m, 2H), 
6.85 – 6.91 (m, 2H), 7.20 – 7.24 (m, 1H), 7.26 (s, 1H), 7.29 – 
7.45 (m, 4H), 7.95 – 8.00 (m, 2H), 8.11 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 21.8, 37.6, 55.3, 114.0, 126.6, 127.8, 128.6, 
129.6, 129.8, 131.5, 131.9, 132.2, 132.5, 135.6, 141.1, 145.2, 158.0, 
166.4; IR (neat, cm-1): 3354, 3259, 3067, 2836, 1665, 1597, 
1573, 1508, 1443, 1355, 1242, 1170; HRMS (ESI): calcd for 
C22H22NO4S [(M+H)+]: 396.1264, found 396.1257. 
2-(4-Fluorobenzyl)-N-tosylbenzamide (3d). White solid 
(0.96 g, 84%), m.p. 119 – 120 °C; 1H NMR (400 MHz, CDCl3) 
δ 2.47 (s, 3H), 4.05 (s, 2H), 6.72 – 6.81 (m, 2H), 6.85 – 6.92 
(m, 2H), 7.16 – 7.25 (m, 2H), 7.33 (m, 2H), 7.38 (m, 1H), 7.46 
(m, 1H), 7.87 – 7.96 (m, 2H), 8.75 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 21.8, 37.8, 115.2 (d, J = 21.3 Hz, CHCF), 126.8, 127.9, 
128.6, 129.7, 130.2 (d, J = 7.8 Hz, CHCHCF), 131.6, 132.1, 135.5, 
135.9 (d, J = 3.1 Hz, CF), 140.8, 145.31, 160.2, 162.6, 166.3; 19F 
NMR (377 MHz, CDCl3) δ -116.8; IR (neat, cm-1): 3248, 3102, 
2856, 1677, 1597, 1575, 1506, 1412, 1345, 1220, 1188, 1165, 1062; 
HRMS (ESI): calcd for C21H19 FNO3S [(M+H)+]: 384.1064, 
found 384.1068. 
2-(4-(tert-Butyl)benzyl)-N-tosylbenzamide, (3e). White 
solid (1.12 g, 89%), m.p. 150 – 151 °C; 1H NMR (400 MHz, 
CDCl3) δ 1.28 (s, 9H), 2.47 (s, 3H), 4.03 (s, 2H), 6.91 (d, J = 
8.1 Hz, 2H), 7.15 – 7.25 (m, 4H), 7.32 – 7.46 (m, 4H), 7.99 (d, 
J = 8.2 Hz, 2H), 8.45 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
21.8, 31.5, 34.4, 37.9, 125.6, 126.6, 127.8, 128.5, 128.7, 129.7, 
131.5, 131.9, 132.6, 135.7, 137.1, 140.9, 145.2, 149.2, 166.5; 
IR (neat, cm-1): 3258, 2960, 1702, 1594, 1513, 1409, 1345, 1162, 
1042, 660; HRMS (ESI): calcd for C25H28NO3S [(M+H)+]: 
422.1784, found 422.1792. 
2-(4-chlorobenzyl)-N-tosylbenzamide (3f). White solid 
(0.63 g, 52%), m.p. 111 – 112 °C; 1H NMR (400 MHz, CDCl3) 
δ 2.47 (s, 3H), 4.04 (s, 2H), 6.80 – 6.86 (m, 2H), 6.99 – 7.05 
(m, 2H), 7.19 (d, J = 7.7 Hz, 1H), 7.22 – 7.29 (m, 1H), 7.33 (d, 
J = 8.1 Hz, 2H), 7.36 – 7.43 (m, 1H), 7.45 (dd, J = 7.6, 1.4 Hz, 
1H), 7.87 – 7.93 (m, 2H), 8.44 – 8.54 (m, 1H); 13C NMR (101 
MHz, CDCl3) δ 21.9, 37.9, 127.0, 127.9, 128.5, 128.6, 129.7, 
130.2, 131.8, 132.0, 132.2, 132.4, 135.5, 138.7, 140.6, 145.3, 166.2; 
IR (neat, cm-1): 3068, 2868, 1672, 1597, 1573, 1436, 1357, 1254, 
1169, 1088, 1069; HRMS (ESI): calcd for C21H19ClNO3S 
[(M+H)+]: 400.0769, found 400.0779. 
2-Benzyl-4-methyl-N-tosylbenzamide (3g). White solid 
(0.83 g, 73%), m.p. 126 – 127 °C; 1H NMR (400 MHz, CDCl3) 
δ 2.28 (s, 3H), 2.45 (s, 3H), 4.04 (s, 2H), 6.93 – 7.01 (m, 2H), 
7.07 (d, J = 7.8 Hz, 1H), 7.16 (m, 4H), 7.28 – 7.35 (m, 3H), 
7.95 (m,  2H), 8.97 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 20.7, 
21.7, 37.9, 126.0, 128.4, 128.4, 128.47, 128.7, 129.6, 131.4, 132.1, 
132.6, 135.5, 136.3, 137.6, 140.4, 145.0, 166.7; IR (neat, cm-1): 
3188, 2920, 1695, 1672, 1595, 1490, 1429, 1341, 1294, 1167, 1062; 
HRMS (ESI): calcd for C22H22NO3S [(M+H)+]: 380.1315, 
found 380.1312. 
2-Benzyl-4-methoxy-N-tosylbenzamide (3h). White solid 
(0.78 g, 66%), m.p. 147 – 148 °C; 1H NMR (400 MHz, CDCl3) 
δ 2.45 (s, 3H), 3.74 (s, 3H), 4.10 (s, 2H), 6.66 – 6.73 (m, 2H), 
6.93 – 7.00 (m, 2H), 7.09 – 7.18 (m, 3H), 7.31 (d, J = 8.1 Hz, 
2H), 7.47 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 8.4 Hz, 2H), 8.71 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ 21.8, 38.7, 55.4, 111.1, 117.6, 
124.2, 126.2, 128.5, 128.53, 128.9, 129.6, 130.3, 135.7, 140.1, 
143.9, 144.9, 162.3, 166.0; IR (neat, cm-1): 3208, 3028, 2927, 
2857, 1692, 1594, 1492, 1449, 1422, 1345, 1235, 1171; HRMS 
(ESI): calcd for C22H22NO4S [(M+H)+]: 396.1264, found 
396.1263. 
2-Benzyl-4-fluoro-N-tosylbenzamide (3i). White solid (0.85 
g, 74%), m.p. 137 – 138 °C; 1H NMR (400 MHz, CDCl3) δ 2.45 
(s, 3H), 4.05 (s, 2H), 6.81 – 6.93 (m, 2H), 6.93 – 7.01 (m, 2H), 
7.12 – 7.21 (m, 3H), 7.32 (d, J = 8.1 Hz, 2H), 7.44 – 7.51 (m, 
1H), 7.89 – 7.97 (m, 2H), 8.80 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 21.7, 38.3, 113.5 (d, J = 21.8 Hz), 118.3 (d, J = 22.0 Hz), 
126.5, 128.4 (d, J = 3.2 Hz), 128.5, 128.6, 128.8, 129.6, 130.2 (d, 
J = 9.3 Hz), 135.3, 139.2, 144.5 (d, J = 8.1 Hz), 145.2 , 163.1, 
165.6; 19F NMR (283 MHz, CDCl3) δ -106.2; IR (neat, cm-1): 
3105, 1674, 1597, 1581, 1454, 1439, 1358, 1237, 1175; HRMS 
(ESI): calcd for C21H19FNO3S [(M+H)+]: 384.1064, found 
384.1058. 
2-(1-Phenylethyl)-N-tosylbenzamide (3j). White solid (0.69 
g, 61%), m.p. 132 – 133 °C;  1H NMR (400 MHz, CDCl3) δ 1.51 
 (d, J = 7.2 Hz, 3H), 2.46 (s, 3H), 4.56 (q, J = 7.2 Hz, 1H), 6.97 
– 7.05 (m, 2H), 7.08 – 7.23 (m, 4H), 7.28 – 7.44 (m, 5H), 7.92 
– 8.00 (m, 2H), 8.33 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
21.9, 22.0, 39.8, 126.3, 126.3, 127.3, 127.7, 128.4, 128.5, 128.7, 
129.7, 131.8, 132.9, 135.6, 145.3, 145.3, 145.5, 166.8; IR (neat, 
cm-1): 3223, 3020, 2981, 1710, 1596, 1574, 1403, 1341, 1230, 1164; 
HRMS (ESI): calcd for C22H22NO3S [(M+H)+]: 380.1315, 
found 380.1295.  
(1R,2S)-2-Benzyl-N-tosylcyclohexanecarboxamide (3k). 
White solid (0.89 g, 80%), m.p. 107 – 108 °C; 1H NMR (400 
MHz, CDCl3) δ 0.82 (q, J = 11.5, 10.9 Hz, 1H), 0.94 – 1.23 (m, 
2H), 1.31 – 1.45 (m, 1H), 1.50 – 1.65 (m, 2H), 1.64 – 1.90 (m, 
3H), 1.90 – 2.14 (m, 2H), 2.39 (s, 3H), 2.50 (dd, J = 13.1, 2.6 
Hz, 1H), 6.88 – 7.00 (m, 2H), 7.11 – 7.23 (m, 3H), 7.28 – 7.35 
(m, 2H), 8.00 (d, J = 8.3 Hz, 2H), 8.98 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 21.8, 25.3, 25.4, 30.1, 30.2, 40.8 (2C), 51.7, 
126.0, 128.2, 128.5, 129.4, 129.8, 135.7, 139.7, 145.3, 174.1; 
IR (neat, cm-1): 3185, 2933, 2857, 1677, 1597, 1493, 1448, 1353, 
1173, 1133, 1086; HRMS (ESI): calcd for C21H26NO3S [(M+H)+]: 
372.1628, found 372.1624. 
Procedure for the synthesis of 2-(4-Methylbenzyl)-N-
nosylbenzamide (3l). Following a reported procedure,22 
to a suspension of EDCl·HCl (0.11 g, 0.52 mmol) in CH2Cl2 
(5ml) was added DMAP (0.12 g, 1.05 mmol) and the mixture 
was stirred at room temperature for 15 min or until the sol-
ids dissolved. Then, the reaction was cooled to 0°C and was 
added 2-(4-methylbenzyl)benzoic acid (0.1 g, 0.44 mmol) 
followed by p-nitrobenzenesulfonamide (0.12 g, 0.59 
mmol) and the mixture was stirred for 24 h at room tem-
perature. Diethyl ether was added and the organic mixture 
was washed with aqueous HCl (2M). The aqueous layer was 
extracted with EtOAc and the organic layers was pooled, 
washed with brine, dried over Na2SO4. The volatiles were 
removed under reduced pressure and the resulting solid 
was purified by column chromatography using an EtOAc: 
hexane (5:5) mix as eluent to yield the pure product. White 
solid (0.14 g, 79%), m.p. 167-168 °C; 1H NMR (500 MHz, 
(CD3)2CO) δ 2.20 (s, 3H), 4.04 (s, 2H), 6.77 (d, J = 7.9 Hz, 
2H), 6.87 (d, J = 7.9 Hz, 2H), 7.32 – 7.27 (m, 2H), 7.46 (t, J = 
7.8 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 8.26 (d, J = 9.3 Hz, 2H), 
8.40 (d, J = 7.9 Hz, 2H); 13C NMR (500 MHz, (CD3)2CO) δ 
19.9, 37.3, 124.0, 126.1, 127.1, 128.3, 128.5, 128.7, 128.7, 128.9, 
129.5, 130.4, 131.2, 131.4, 135.0, 137.5, 140.7; IR (neat, cm-1): 
3106, 2924, 1684, 1526, 1426, 1351, 1243, 1181, 1059; HRMS 
(ESI): calcd for C21H18N2O5S [(M+Na)+]: 433.0828, found 
433.0832. 
Sulfamidation Optimization Study (Table 1). 
The optimization study was performed according to gen-
eral procedure given below, varied according to the entries 
in Table 1. The product, 4a, was not isolated, rather the 
spectroscopic yield of 4a was determined by 1H NMR spec-
troscopy, using an internal standard (1,3,5-trimethoxyben-
zene). 
General Procedure for the Synthesis of Isoin-
dolinones, 4 (Table 1). The appropriate substrate 3 (0.3 
mmol), Cu(OTf)2 (22 mg, 0.06 mmol) and PhI(OAc)2 (193 
mg, 0.6 mmol) were added to a Young’s tube under atmos-
pheric conditions. Chlorobenzene (5 ml) and acetic acid (1 
ml) were added sequentially and the tube was sealed with 
a PTFE tap. The reaction vessel was heated to 120 °C and 
stirred at this temperature for 16 hrs. After cooling to room 
temperature the volatiles were removed under reduced 
pressure and the crude product was subjected to column 
chromatography using an EtOAc: petroleum ether (40-60 
°C) 1:3 mix as eluent to yield the pure product. 
3-Phenyl-2-tosylisoindolin-1-one (4a). White solid 
(66 mg, 61%). The spectroscopic data are in agreement 
with the literature 23, m.p. 173 – 174 °C; 1H NMR (400 MHz, 
CDCl3) δ 2.36 (s, 3H), 6.22 (s, 1H), 7.05 – 7.10 (m, 2H), 7.10 
– 7.18 (m, 3H), 7.22 – 7.35 (m, 3H), 7.43 – 7.59 (m, 4H), 7.86 
(d, J = 7.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 21.8, 65.8, 
123.9, 124.9, 128.2, 128.3, 128.8, 128.9, 129.0, 129.1, 129.3, 134.5, 
136.1, 137.1, 144.8, 146.6, 166.6; IR (neat, cm-1): 3066, 1722, 
1597, 1493, 1458, 1365, 1285, 1168; HRMS (ESI): calcd for 
C21H18NO3S [(M+H)+]: 364.1002, found 364.1002. 
3-(p-Tolyl)-2-tosylisoindolin-1-one (4b). White 
solid (86 mg, 74%), m.p. 185 – 186 °C; 1H NMR (400 MHz, 
CDCl3) δ 2.34 (s, 3H), 2.36 (s, 3H), 6.19 (s, 1H), 6.94 – 7.00 
(m, 2H), 7.04 – 7.09 (m, 2H), 7.11 – 7.18 (m, 4H), 7.42 – 7.48 
(m, 1H), 7.51 – 7.57 (m, 3H), 7.84 (dd, J = 7.6, 0.8 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 21.1, 21.6, 65.4, 123.6, 124.6, 
127.9, 128.1, 128.8, 128.8, 129.1, 129.3, 133.9, 134.2, 135.9, 138.5, 
144.6, 146.5, 166.4; IR (neat, cm-1): 1730, 1610, 1595, 1468, 1351, 
1286, 1168, 1099, 1019; HRMS (ESI): calcd for C22H20NO3S 
[(M+H)+]: 378.1158, found 378.1159. 
3-(4-Methoxyphenyl)-2-tosylisoindolin-1-one (4c). 
White solid (84 mg, 71%), m.p. 161 – 162 °C; 1H NMR (400 
MHz, CDCl3) δ 2.35 (s, 3H), 3.80 (s, 3H), 6.19 (s, 1H), 6.74 – 
6.80 (m, 2H), 6.95 – 7.02 (m, 2H), 7.11 – 7.19 (m, 3H), 7.42 – 
7.49 (m, 1H), 7.49 – 7.59 (m, 3H), 7.84 (dd, J = 7.6, 1.0 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 21.7, 55.5, 65.4, 114.1, 123.8, 
124.7, 128.2, 128.9, 129.0, 129.0, 129.3, 129.6, 134.4, 136.2, 
144.7, 146.8, 160.0, 166.5; IR (neat, cm-1): 2928, 2836, 1728, 
1608, 1597, 1510, 1466, 1348, 1248, 1167, 1084; HRMS (ESI): 
calcd for C22H19NO4S [(M+H)+]: 394.1108, found 394.1118. 
3-(4-fluorophenyl)-2-tosylisoindolin-1-one, (4d). 
White solid (84 mg, 74%), m.p. 141 – 142 °C; 1H NMR (400 
MHz, CDCl3) δ 2.37 (s, 3H), 6.21 (s, 1H), 6.91 – 6.99 (m, 2H), 
7.04 – 7.10 (m, 2H), 7.12 – 7.19 (m, 3H), 7.44 – 7.60 (m, 4H), 
7.82 – 7.91 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 21.8, 65.0, 
115.8 (d, J = 22.4 Hz), 123.8, 125.0, 128.2, 129.0, 129.3, 129.4, 
130.0 (d, J = 8.8 Hz), 133.0, 134.6, 136.1, 145.0, 146.3, 162.9 (d, 
J = 248 Hz), 166.4; 19F NMR (377 MHz, CDCl3) δ -112.5; 
IR (neat, cm-1): 2922, 2853, 1760, 1719, 1679, 1508, 1287, 1226, 
1185, 1168; HRMS (ESI): calcd for C21H16FNO3S [(M+H)+]: 
382.0908, found 382.0910. 
3-(4-(tert-butyl)phenyl)-2-tosylisoindolin-1-one, 
(4e). White solid (89 mg, 71%), m.p. 230 – 231 °C; 1H NMR 
(400 MHz, CDCl3) δ 1.31 (s, 9H), 2.34 (s, 3H), 6.20 (s, 1H), 
6.93 – 6.98 (m, 2H), 7.05 – 7.10 (m, 2H), 7.16 – 7.21 (m, 1H), 
7.21 – 7.25 (m, 2H), 7.41 – 7.49 (m, 3H), 7.53 – 7.58 (m, 1H), 
7.87 (d, J = 7.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 21.7, 
31.4, 34.7, 65.5, 123.9, 124.7, 125.6, 128.0, 128.1, 129.0, 129.1, 
129.2, 133.7, 134.4, 136.2, 144.6, 146.6, 151.9, 166.5; IR (neat, 
cm-1): 3668, 2965, 2928, 2863, 1736, 1718, 1594, 1493, 1554, 
1358, 1168, 1106, 1085; HRMS (ESI): calcd for C25H26NO3S 
[(M+H)+]: 420.1628, found 420.1625. 
 3-(4-chlorophenyl)-2-tosylisoindolin-1-one, (4f). 
White solid (86 mg, 72%), m.p. 83 – 84 °C; 1H NMR (400 
MHz, CDCl3) δ 2.38 (s, 3H), 6.18 (s, 1H), 7.00 – 7.06 (m, 2H), 
7.11 – 7.20 (m, 3H), 7.21 – 7.26 (m, 2H), 7.45 – 7.51 (m, 1H), 
7.54 – 7.60 (m, 3H), 7.83 – 7.88 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 21.8, 64.9, 123.8, 125.0, 128.2, 128.9, 129.1, 129.4, 
129.4, 129.5, 134.6, 134.8, 135.7, 136.0, 145.1, 146.0, 166.4; 
IR (neat, cm-1): 3092, 2922, 2853, 1734, 1610, 1594, 1491, 1468, 
1359, 1288, 1169, 1087; HRMS (ESI): calcd for C21H17ClNO3S 
[(M+H)+]: 398.0612, found 398.0622. 
5-methyl-3-phenyl-2-tosylisoindolin-1-one (4g). 
White solid (83 mg, 73%), m.p. 184 – 185 °C; 1H NMR (400 
MHz, CDCl3) δ 2.36 (s, 3H), 2.41 (s, 3H), 6.17 (s, 1H), 7.01 – 
7.10 (m, 3H), 7.13 (d, J = 8.3 Hz, 2H), 7.22 – 7.26 (m, 2H), 
7.28 – 7.39 (m, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.65 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 21.4, 21.7, 65.6, 123.6, 124.8, 128.2, 
128.2, 128.7, 128.8, 129.1, 129.3, 135.6, 136.2, 137.3, 139.4, 144.0, 
144.8, 166.7; IR (neat, cm-1): 2917, 1720, 1594, 1493, 1362, 1185, 
1079; HRMS (ESI): calcd for C22H20NO3S [(M+H)+]: 378.1158, 
found 378.1162. 
5-Methoxy-3-phenyl-2-tosylisoindolin-1-one (4h). 
White solid (83 mg, 73%), m.p. 208 – 209 °C; 1H NMR (400 
MHz, CDCl3) δ 2.35 (s, 3H), 3.76 (s, 3H), 6.14 (s, 1H), 6.56 
(d, J = 2.2 Hz, 1H), 6.97 (dd, J = 8.5, 2.1 Hz, 1H), 7.05 – 7.16 
(m, 4H), 7.22 – 7.36 (m, 3H), 7.47 – 7.52 (m, 2H), 7.76 (d, J 
= 8.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 21.7, 55.9, 65.4, 
107.7, 116.6, 121.4, 126.5, 128.2, 128.2, 128.8, 128.9, 129.3, 136.3, 
137.3, 144.7, 149.1, 165.0, 166.2; IR (neat, cm-1): 2942, 1727, 
1605, 1490, 1359, 1295, 1244, 1169, 1094, 1080; HRMS (ESI): 
calcd for C22H20NO4S [(M+H)+]: 394.1108, found 394.1120. 
5-Fluoro-3-phenyl-2-tosylisoindolin-1-one (4i). 
White solid (55 mg, 47%), m.p. 170 – 171 °C; 1H NMR (400 
MHz, Cdcl3) δ 2.36 (s, 3H), 6.18 (s, 1H), 6.80 – 6.87 (m, 1H), 
7.04 – 7.09 (m, 2H), 7.10 – 7.19 (m, 3H), 7.24 – 7.31 (m, 2H), 
7.31 – 7.37 (m, 1H), 7.47 – 7.52 (m, 2H), 7.82 – 7.90 (m, 1H); 
13C NMR (101 MHz, CDCl3) δ 21.7, 65.2, 111.1 (d, J = 24.6 Hz), 
117.4 (d, J = 24.0 Hz), 125.1, 127.2 (d, J = 10.0 Hz), 128.1, 128.2, 
129.0, 129.0, 129.3, 135.9, 136.4, 144.9, 149.0 (d, J = 10.2 Hz), 
165.3 (d, J = 255.5 Hz), 168.0; 19F NMR (377 MHz, CDCl3) δ -
101.7; IR (neat, cm-1): 3069, 2920, 1718, 1618, 1600, 1483, 1367, 
1304, 1261, 1239, 1169; HRMS (ESI): calcd for C21H17FNO3S 
[(M+H)+]: 382.0908, found 382.0903. 
3-methyl-3-phenyl-2-tosylisoindolin-1-one (4j). 
White solid (52 mg, 46%), m.p. 71 – 72 °C; 1H NMR (400 
MHz, CDCl3) δ 2.37 (s, 3H), 2.40 (s, 3H), 7.05 – 7.10 (m, 1H), 
7.13 – 7.22 (m, 4H), 7.22 – 7.34 (m, 3H), 7.39 – 7.47 (m, 1H), 
7.50 – 7.59 (m, 3H), 7.83 (d, J = 7.6 Hz, 1H); 13C NMR (101 
MHz, CDCl3) δ 21.7, 25.4, 71.7, 122.4, 124.7, 127.1, 127.5, 128.2, 
128.6, 128.8, 128.8, 129.1, 134.7, 136.4, 139.7, 144.8, 153.2, 166.8; 
IR (neat, cm-1):2921, 2851, 1725, 1611, 1597, 1494, 1466, 1448, 
1357, 1289, 1260, 1167; HRMS (ESI): calcd for C22H20NO3S 
[(M+H)+]: 378.1158, found 378.1157. 
 (3aR,7aR)-3-Phenyl-2-tosyloctahydro-1H-isoindol-
1-one (4k). White solid (52 mg, 47%), m.p. 173 – 174 °C; 1H 
NMR (400 MHz, CDCl3) δ 1.15 – 1.28 (m, 4H), 1.53 – 1.86 (m, 
4H), 1.96 – 2.19 (m, 2H), 2.41 (s, 3H), 4.72 (d, J = 9.9 Hz, 1H), 
7.15 (d, J = 2.3 Hz, 2H), 7.21 (d, J = 8.6 Hz, 2H), 7.27 – 7.33 
(m, 3H), 7.57 – 7.63 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
21.8, 25.2, 25.3, 25.4, 27.5, 48.5, 49.6, 69.8, 127.3, 128.3, 128.6, 
129.2, 129.3, 136.6, 138.7, 144.6, 175.0; IR (neat, cm-1):2928, 
2857, 1736, 1594, 1493, 1454, 1357, 1159, 1106; HRMS (ESI): 
calcd for C21H24NO3S [(M+H)+]: 370.1471, found 370.1467. 
3-(p-Tolyl)-2-nosylisoindolin-1-one (4l). White 
solid (96 mg, 78%), m.p. 201-202 °C; 1H NMR (500 MHz, 
CDCl3) δ; 2.36 (s, 3H), 6.23 (s, 1H), 6.91 (d, J = 8.3 Hz, 2H), 
7.06 (d, J = 7.6 Hz, 2H), 7.19 (dd, J = 7.6, 0.7 Hz, 1H), 7.52 (t, 
J = 7.5 Hz, 1H), 7.62 (t, J = 8.2 Hz,  1H), 7.77 (d, J = 9.1 Hz, 
2H), 7.90 (d, J = 7.9 Hz, 1H), 8.14 (d, J = 9.1 Hz, 2H); 13C NMR 
(500 MHz, CDCl3) δ 21.1, 65.6, 123.6, 123.8, 124.8, 128.2, 128.3, 
129.2, 129.2, 129.4, 133.1, 134.8, 139.2, 144.3, 146.3, 150.3, 166.2; 
IR (neat, cm-1): 2928, 2857, 1722, 1528, 1384, 1348, 1285, 1176, 
1102, 855; HRMS (ESI): calcd for C21H16N2O5S [(M+Na)+]: 
431.067213, found 431.066711. 
Procedure for the Deprotection of N-Sulfonyl 
Isoindolinones. Following a reported procedure,13 to a so-
lution of SmI2 (26.4 ml, 0.1 M, 2.64 mmol) in THF was 
added the protected isoindolinone (4b or 4l) (0.264 
mmol), water (142 µL, 7.92 mmol) and pyrrolidine (0.44 ml, 
5.28 mmol) under a nitrogen atmosphere. The mixture of 
reaction was diluted with diethyl ether (20 ml) and a solu-
tion of potassium sodium tartrate and potassium car-
bonate (10% w/v each) was added. The aqueous phase was 
extracted with diethyl ether and the organic extract was 
dried over Na2SO4. The volatiles were removed under re-
duced pressure and the resulting crude product was dis-
solved in DCM and purified by ion exchange column 
(propylsulfonic acid functionalized silica) to yield the pure 
product. White solid (36 mg, 62%, from 4b) and (42 mg, 71 
%, from 4l). The spectroscopic data are in agreement with 
the literature,24 m.p. 179-181 °C; 1H NMR (400 MHz, DMSO) 
δ 2.29 (s, 3H), 5.69 (s, 1H), 7.18 (s, 4H), 7.29 (dd, J = 0.9, 7.3 
Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.56 (td, J = 1.3, 7.3 Hz, 1H), 
7.72 (d, J = 7.1 Hz, 1H), 9.02 (s, 1H); 13C NMR (400 MHz, 
CDCl3) δ 21.2, 60.7, 123.4, 123.9, 126.8, 128.4, 129.8, 131.7, 
132.4, 135.4, 138.5, 148.2, 171.0; IR (neat, cm-1): 3183, 3063, 
2859, 1681, 1607, 1510, 1465, 1357, 1299, 1264, 1139, 1022, 951, 
849; HRMS (ESI): calcd for C15H13NO[(M+Na)+]: 246.0889, 
found 246.0900. 
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